A Phase 2 entry is now marked completed and a Phase 3 entry registered in Indonesia is marked active, not recruiting. Both were updated on 13 October 2026.
Bethesda, Maryland, 13 October 2026 — Two ClinicalTrials.gov registry records sponsored by BrightGene Bio-Medical Technology Co., Ltd. were last updated on 13 October 2026.
The Phase 2 interventional record with identifier NCT06911203 carries the overall status completed. The Phase 3 interventional record with identifier NCT07064486, registered in Indonesia, carries the overall status active, not recruiting. Neither record reports a result; a registry entry records what a sponsor registered and the state that entry is in.
Source documents
-
A Study of BGM0504 in Participants With Obesity
- Identifier
- Registry identifier NCT06911203
- Registry status
- COMPLETED
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Last update posted
- 2026-10-13
-
A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia
- Identifier
- Registry identifier NCT07064486
- Registry status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Last update posted
- 2026-10-13